For information on our next seed round, please email: invest@receptor.ai
MEMBRANOTROPIC DRUG DISCOVERY
COMING SOON
Membranotropic Drug Discovery for
RECEPTOR.AI makes the cell membranes druggable to provide new treatments for cancer and cardiovascular diseases.
|
Partnership
10% of designed protein-targeting molecules have validated biological activity
10%
Average success rate
Ability to get the hits with characteristics of the leads in one shot
st
1
The result from the 1st iteration
Virtual screening of the chemical space with more than a quintillion of diverse molecules
10
Chemical Space
16
Time- and cost-efficient synthesis of novel and diverse molecules
80%
Synthesisabilty
RECEPTOR.AI Membranotropic Technology for Drug Discovery
Double targeting of the protein-membrane system as a first-class druggable entity.
Drug Candidate Success Scoring
Advanced scoring of drug candidate success rate in clinical trials is powered by in-depth experimental data and molecular characteristics analysis
Target Identification
Rapid identification of potential targets navigating in a multiparametric map that embraces all possible relationships of biological entities
Our engine is a robust scientific data processor trained to establish different biological relationships between diseases, proteins, genes and drugs, etc
Receptor AI Knowledge Engine
Projects Pipeline
Collaborations & Partnerships
Revolutionize Drug Discovery with our Smart AI Services
Pharma Companies
Biotech Companies
Academic Research
Pharmaceutical Investment
Subscribe to Updates
No Spam. Cancel Anytime.
© 2021-2022 RECEPTOR AI | All Rights Reserved.
Cookies managing
Cookie Settings
Cookies necessary for the correct operation of the site are always enabled.
Other cookies are configurable.
Other cookies are configurable.